Publications by authors named "Ryan Marsh"
Article Synopsis
- A pilot study explored the effects of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy on gut microbiota, metabolomic functioning, and clinical outcomes in people with cystic fibrosis (CF), using faecal samples collected from 20 participants at multiple time points.
- The results showed that while ETI therapy increased diversity and moved the gut microbiota composition closer to that of healthy controls, significant differences remained, particularly influenced by concurrent antibiotic treatments for lung infections.
- The study concludes that further research is needed to better understand how CFTR modulator therapies and antibiotics affect the gut microbiome in CF patients, suggesting the use of integrated omics approaches for future investigations.*
People with cystic fibrosis (pwCF) experience a range of persistent gastrointestinal symptoms throughout life. There is evidence indicating interaction between the microbiota and gut pathophysiology in CF. However, there is a paucity of knowledge on the potential effects of CF transmembrane conductance regulator (CFTR) modulator therapies on the gut microbiome.
View Article and Find Full Text PDFBackground: Most people with cystic fibrosis (pwCF) suffer from gastrointestinal symptoms and are at risk of gut complications. Gut microbiota dysbiosis is apparent within the CF population across all age groups, with evidence linking dysbiosis to intestinal inflammation and other markers of health. This pilot study aimed to investigate the potential relationships between the gut microbiota and gastrointestinal physiology, transit, and health.
View Article and Find Full Text PDF